What is Bio-Techne Corp.'s market cap?

Bio-Techne Corp. (TECH) has a market capitalization of $11.3B and trades on NASDAQ.

What is Bio-Techne Corp.'s revenue and profitability?

Bio-Techne Corp. generated $1.2B in trailing twelve-month revenue with net income of $181.9M, representing a net margin of 15.0%. Gross margin stands at 65.8%, with free cash flow of $263.2M. The latest reported period is Q4 2026.

Who are Bio-Techne Corp.'s competitors?

Bio-Techne Corp.'s key competitors include Thermo Fisher Scientific Inc., Danaher Corporation, 10x Genomics, and others. These companies compete in similar markets and product categories.

Who does Bio-Techne Corp. partner with?

Bio-Techne Corp.'s notable partners include Wilson Wolf Corporation.

What subsidiaries does Bio-Techne Corp. have?

Bio-Techne Corp.'s subsidiaries include Lunaphore SA, Research and Diagnostic Systems, Inc..

Where is Bio-Techne Corp. headquartered?

Bio-Techne Corp. is headquartered in United States of America and employs approximately 3,050 people. It has been publicly traded since 1989.

Bio-Techne Corp. (TECH) Stock Fundamentals & Financials

Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells high-quality reagents, instruments, and services for the research, diagnostics, and bioprocessing markets.

Market cap

$11.34B+41.5%

Revenue$1.2B-0.4%

Net income$181.9M+38.1%

Free cash flow$263.2M+2.6%

EPS (diluted)$1.15+38.6%

Trailing twelve months · change vs. prior year

Earnings

Q4 2026 report

August 12, 2026

Revenue$321.2MBeat by $6.6M EPS$0.52Beat by $0.00

Read the full report

Next report

Nov 4, 2026 (in 2 months)

Revenue estimate$292.4M

EPS estimate$0.46

Financials

Q4 2026

Income statement

See full

Revenue$321.2M+1.3%

Gross profit$211.4M+6.3%

Operating income$74.3M—

Net income$54.6M—

EPS (diluted)$0.35—

Balance sheet

See full

Cash & equivalents$264.7M+63.2%

Total debt$289.1M-34.9%

Total equity$2.1B+9.9%

Total assets$2.6B+1.1%

Cash flow

See full

Operating cash flow$95.4M-2.8%

CapEx$8.5M+73.4%

Free cash flow$86.9M-6.8%

Valuation & ratios

Valuation

See full

Market cap$11.34B+41.5%

Enterprise value$11.37B+37.0%

P/E62.4×—

P/S9.3×+2.8×

Profitability

See full

Gross margin65.8%+1.0pp

Operating margin20.7%—

Net margin15%—

FCF margin21.7%+0.6pp

Returns & leverage

See full

Return on equity9%—

Debt / equity0.1×-0.1×

Current ratio4.5×+1.1×

Segments

By product

See full

Consumables$260.7M+3.1%

Instruments$31.5M+9.1%

Service$23.1M-22.1%

Royalty$5.9M+6.5%

By segment

See full

Protein Sciences$231.2M+2.1%

Diagnostics And Spatial Biology$90.1M+0.5%

Competitors

By market cap

Thermo Fisher Scientific$239.76B+34.3%

Danaher$146.47B+6.0%

Agilent Technologies$43.3B+20.6%

Revvity$16.3B+64.1%

TEC

Bio-Techne Corp.$11.3B+41.5%

Bio-Rad Laboratories$10.1B+33.6%

10x Genomics, Inc.$9.5B+491%

Standard BioTools Inc.$278.4M-46.0%

By revenue growth

Agilent Technologies+8.6%

Thermo Fisher Scientific+5.6%

Danaher+4.6%

Revvity+4.1%

Bio-Rad Laboratories+1.9%

TEC

Bio-Techne Corp.-0.4%

10x Genomics, Inc.-4.3%

By net margin

Agilent Technologies19.53%+1.6pp

Danaher15.95%+1.7pp

Thermo Fisher Scientific15.19%0.0pp

TEC

Bio-Techne Corp.14.97%+4.2pp

Revvity8.16%-2.0pp

Bio-Rad Laboratories6.52%+91.7pp

10x Genomics, Inc.-12.18%+0.9pp

Profile

Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells high-quality reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. The company provides essential tools for scientific investigations into biological processes, drug discovery, and molecular diagnostics. Its portfolio supports researchers and clinicians in understanding disease progression and delivering accurate clinical tests.

Competitive position

A leading provider of biological content and proteomic tools with a disciplined acquisition strategy to maintain a first-to-market advantage in high-growth life science niches.

GeographiesNorth America, Europe, Asia, United Kingdom, Canada, Switzerland, China

Customer segmentsAcademic Institutions, Biopharmaceutical Companies, Clinical Diagnostic Labs

Business modelManufacturing, Direct-to-Customer Sales, B2B Reagents and Consumables

SuppliersRaw Material Suppliers, Specialized Chemical Providers, Laboratory Equipment Components

CustomersAcademic Research Labs, Contract Research Organizations (CROs), Hospitals and Health Systems, Biotech Startups

CountryUnited States of America

Listed1989

Employees3.1K

CEOKim Kelderman

SectorHealthcare

IndustryBiotechnology

Websitebio-techne.com

FilingsSEC EDGAR

FAQ

What is Bio-Techne Corp.'s market cap?: Bio-Techne Corp. (TECH) has a market capitalization of $11.3B and trades on NASDAQ.
What is Bio-Techne Corp.'s revenue and profitability?: Bio-Techne Corp. generated $1.2B in trailing twelve-month revenue with net income of $181.9M, representing a net margin of 15.0%. Gross margin stands at 65.8%, with free cash flow of $263.2M. The latest reported period is Q4 2026.
Who are Bio-Techne Corp.'s competitors?: Bio-Techne Corp.'s key competitors include Thermo Fisher Scientific Inc., Danaher Corporation, 10x Genomics, and others. These companies compete in similar markets and product categories.
Who does Bio-Techne Corp. partner with?: Bio-Techne Corp.'s notable partners include Wilson Wolf Corporation.
What subsidiaries does Bio-Techne Corp. have?: Bio-Techne Corp.'s subsidiaries include Lunaphore SA, Research and Diagnostic Systems, Inc..
Where is Bio-Techne Corp. headquartered?: Bio-Techne Corp. is headquartered in United States of America and employs approximately 3,050 people. It has been publicly traded since 1989.

Ask your AI about Bio-Techne Corp..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude